Annual Report

The report describes Pharming's 2017 transition to profitability, with revenue reaching EUR 89.6 million and operating profit EUR 21.9 million. It highlights expansion of direct RUCONEST commercialization in the United States and clinical progress in prophylaxis and pediatric HAE treatment. The report also records 48.5% headcount growth to 150 people, reflecting the company's expanded international operations.